Safety study of immune globulin for primary immunodeficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a primary immunodeficiency (a condition that weakens your immune system).
- You are already enrolled in a special registry for people with primary immunodeficiency.
- Your medical records show that you have used a specific immune globulin treatment (given under the skin).
- Your doctors have recorded whether you had any side effects from treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
This study looks at what is happening in the immune system for people with an inherited (primary) immune problem. It may help researchers better understand the disease and how it works.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.